Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-04-27 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The presence of an audit report with an unqualified opinion from the accounting firm is mentioned, and the document includes comprehensive financial metrics, quarterly data, and detailed business and operational information. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-27 Chinese
科美诊断技术股份有限公司2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and rectification status. The document is a detailed report on internal control evaluation, which is typically part of audit-related disclosures but is not a full annual report or audit opinion by itself. It does not contain full financial statements or comprehensive financial performance data. The document length is 4189 characters, which is relatively short but contains substantive content on internal control evaluation. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2022
2023-04-27 Chinese
科美诊断技术股份有限公司2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (quarterly). The presence of comprehensive financial statements and analysis for a quarter period aligns with the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, which is substantial and contains the actual financial data, not just an announcement or certification. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese
科美诊断技术股份有限公司2022年度非经营性资金占用及其他关联资金往来情况的专项说明
Regulatory Filings
2023-04-27 Chinese
科美诊断技术股份有限公司2022年度内部控制审计报告
Regulatory Filings
2023-04-27 Chinese
科美诊断技术股份有限公司2022年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from the company's board regarding the profit distribution plan for the fiscal year ending December 31, 2022. It details the dividend per share, total dividend amount, and the approval process including board meeting votes, independent director opinions, and supervisory board opinions. The document explicitly states the dividend distribution plan and that it will be submitted to the annual shareholders meeting for approval. There is no detailed financial statement or comprehensive financial analysis present, only the dividend distribution announcement and related procedural information. The document length is short (1524 characters), and it is primarily an announcement of dividend amount and related shareholder meeting procedures. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2023-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.